Literature DB >> 18584239

Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis.

Hou Shan Yao1, Qiang Wang, Wei Jun Wang, Zhi Qian Hu.   

Abstract

BACKGROUND: Allogeneic blood transfusion (ABT) containing packed red blood cells (RBCs) has a known immunosuppressive effect that may affect cancer metastases and recurrence. This study examined whether intraoperative allogeneic RBC transfusion is an independent risk factor of adverse outcome in patients with ampullary carcinoma after curative pancreatoduodenectomy.
METHODS: The clinical data of 67 patients with carcinoma of the ampulla of Vatar underwent pancreatoduodenectomy between 1999 and 2004 were analyzed, and long-term follow-up visits were made for all patients. Kaplan-Meier statistics and Cox proportional hazard methodology were used to perform univariate and multivariate analysis to identify independent risk factors for survival. For the meta-analysis, all English-language studies regarding blood transfusion from carcinoma of the ampulla of Vatar or ampullary carcinoma and prognostic factors or factors for survival from 1995 to 2007 were reviewed, and contingency tables were constructed from which a summary relative risk was calculated.
RESULTS: There were 43 patients (64.2%) who received an intraoperative ABT. The amount of intraoperative ABT ranged from 2 to 13 (mean, 4.25) units; there were 18 patients transfused at 2 units, and 25 patients transfused > or =3 units. The follow-up ranged from 2 to 90 (mean, 49) months. Forty-five patients (67.2%) died as a result of tumor progression. For patients transfused > or =3 units, median and cumulative 3-year and 5-year survivals were poorer significantly than that of patients transfused with 2 units and/or nontransfused patients (P < 0.05). After multivariate analysis, except for presence of lymph node metastasis (P = 0.023) and pancreatic invasion (P = 0.024), the intraoperative ABT > or =3 units was found to be an independent poor prognostic factor for those with ampullary cancer after curative pancreatoduodenectomy either (relative risk, 2.082; 95% confidence interval (CI), 1.048-4.135; P = 0.036). Meta-analysis of 346 patients showed the summary relative risk of an adverse outcome after intraoperative ABT in these studies was 2.55 (95% CI, 1.59-4.1).
CONCLUSIONS: The amount of intraoperative ABT is one of the important factors that adversely influenced survival in patients with ampullary cancer after curative pancreatoduodenectomy. Healing anemia preoperatively and careful dissection to minimize intraoperative bleeding as much as possible are mandatory for reducing risk of the intraoperative ABT.

Entities:  

Mesh:

Year:  2008        PMID: 18584239     DOI: 10.1007/s00268-008-9675-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  42 in total

1.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

2.  Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique.

Authors:  J L Fleiss; A J Gross
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

3.  Adenocarcinoma of the ampulla of Vater. A 28-year experience.

Authors:  M A Talamini; R C Moesinger; H A Pitt; T A Sohn; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Anastomotic leakage after colorectal cancer surgery: a risk factor for recurrence and poor prognosis.

Authors:  S Fujita; T Teramoto; M Watanabe; S Kodaira; M Kitajima
Journal:  Jpn J Clin Oncol       Date:  1993-10       Impact factor: 3.019

6.  Blood transfusions in breast cancer patients undergoing mastectomy: possible importance of timing.

Authors:  M Pysz
Journal:  J Surg Oncol       Date:  2000-12       Impact factor: 3.454

7.  Poor prognosis in esophageal cancer patients with postoperative complications.

Authors:  T Hirai; Y Yamashita; H Mukaida; M Kuwahara; H Inoue; T Toge
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions.

Authors:  J Kaplan; S Sarnaik; J Gitlin; J Lusher
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

9.  Factors predictive of survival in ampullary carcinoma.

Authors:  J R Howe; D S Klimstra; R D Moccia; K C Conlon; M F Brennan
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  Perioperative blood transfusion has prognostic significance for breast cancer.

Authors:  P I Tartter; L Burrows; A E Papatestas; G Lesnick; A H Aufses
Journal:  Surgery       Date:  1985-02       Impact factor: 3.982

View more
  23 in total

1.  Pre- and intraoperative variables affecting early outcomes in elderly patients undergoing pancreaticoduodenectomy.

Authors:  Sebastian G de la Fuente; Kyla M Bennett; Theodore N Pappas; John E Scarborough
Journal:  HPB (Oxford)       Date:  2011-10-12       Impact factor: 3.647

2.  Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection.

Authors:  Fabio Bagante; Gaya Spolverato; Andrea Ruzzenente; Ana Wilson; Faiz Gani; Simone Conci; Alexander Yahanda; Tommaso Campagnaro; Alfredo Guglielmi; Timothy M Pawlik
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

3.  Blood transfusion and postoperative complications: a cautionary comment.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Le-Qun Li
Journal:  Transl Gastroenterol Hepatol       Date:  2016-07-18

Review 4.  [Cell salvage : Scientific evidence, clinical practice and legal framework].

Authors:  T Seyfried; E Hansen
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

5.  Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy.

Authors:  Thilo Welsch; Hanna Eisele; Stefanie Zschäbitz; Ulf Hinz; Markus W Büchler; Moritz N Wente
Journal:  Langenbecks Arch Surg       Date:  2011-05-25       Impact factor: 3.445

6.  Are We Sure that Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy?

Authors:  Han-Yue Mo; Xue-Mei You; Bang-De Xiang; Le-Qun Li; Jian-Hong Zhong
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

7.  Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.

Authors:  Serdar Balci; Olca Basturk; Burcu Saka; Pelin Bagci; Lauren M Postlewait; Takuma Tajiri; Kee-Taek Jang; Nobuyuki Ohike; Grace E Kim; Alyssa Krasinskas; Hyejeong Choi; Juan M Sarmiento; David A Kooby; Bassel F El-Rayes; Jessica H Knight; Michael Goodman; Gizem Akkas; Michelle D Reid; Shishir K Maithel; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2015-03-18       Impact factor: 5.344

8.  Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression.

Authors:  Karen K Lo; Erik A Bey; Biswantha Patra; Douglas D Benson; David A Boothman; Christopher C Silliman; Carlton C Barnett
Journal:  Ann Surg Oncol       Date:  2013-01-18       Impact factor: 5.344

Review 9.  Review of the investigation and surgical management of resectable ampullary adenocarcinoma.

Authors:  James Askew; Saxon Connor
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

Review 10.  Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.

Authors:  J P Cata; H Wang; V Gottumukkala; J Reuben; D I Sessler
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.